Tetrandrine(μM): Sorafenib(μM): Tetrandrine(μM): Sorafenib(μM): A B S 1 Cell viability for the combination of sorafenib and tetrandrine in various concentrations
BEL7402 S 2 Dose-response curves and combination index values (CI ﹤ 1 ) showed the synergistic effect of combination with sorafenib and tetrandrine was existed
Cell cycle for combination of sorafenib and tetrandrine showed no significant alteration S 3 HCT116 BEL7402 ConTet+BayTetBay
Sor - + - + Tet - - + + * Activation of caspase-3 and caspase-9 in BEL7402 cells was determined after treatment with sorafenib and/or tetrandrine for 24 h S 4
S 5 The body weights of nude mice bearing established HCT116 tumor xenografts
GAPDH BEL7402HCT116 Sor - + - + - + - + Tet - - + + - - + + LC3- Ⅰ LC3- Ⅱ Cell viability could not be rescued by the autophagy inhibitor 3-methyladenine (3-MA) or chloroquine (CQ) BEL7402 Cell Viability(%) Sor: - - + + - - + + Tet : - + - + - + - + Inhibitor: - - - - + + + + S 6 A B
TET: - - + + PD: - + - + TET : - - + + PD : - + - + TET : - - + + SB : - + - + TET : - - + + SB : - + - + S 7 A B Cell viability for combination of tetrandrine and PD98059 (A) or SB (B)
A HCT116 WT Bax -/- Bax GAPDH S 8 B C WT Bax - /- WT+S+T Intracellular ROS Bax - /- +S+T WTBax -/- Sorafenib : - - + + Tetrandrine : - - + + ** HCT116 cells with Bax-/- were not sensitive to the combination treatment with sorafenib and tetrandrine as the HCT116 wild type cells